Tagrisso's 1st-line reimb. necessary based on its OS benefit

By | translator Alice Kang

21.05.22 06:00:18

가나다라 0

Tagrisso’s benefit as a first-line treatment highlighted at KSMO’s annual symposium

“Grpah shows clear difference from early phases of administration in the Asian group”

Pointed out that "Korea is moving backwards in midst the advancing global trend "

With ‘Tagrisso (osimertinib)’ winning recognition as the first-line standard treatment for epidermal growth factor receptor (EGFR)-mutated advanced and metastatic non-small cell lung cancer, the demand for its reimbursement as first-line in Korea has also been increasing.

At the Lung Cancer 1 session of the 19th Annual Symposium & General Assembly of the Korean Society of Medical Oncology that was held online on the 21st, Ji-youn Han, Head of the Lung Cancer Center at the National Cancer Center Korea emphasized the need for Tagrisso’s reimbursement based on the clinical data of Tagrisso.

As a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), Tagri

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)